GlobeImmune (GlobeImmune) Dividend Payout Ratio : 0.00 (As of Mar. 2016)

View and export this data going back to 2014. Start your Free Trial

What is GlobeImmune Dividend Payout Ratio?

GlobeImmune's dividend payout ratio for the months ended in Mar. 2016 was 0.00.

The historical rank and industry rank for GlobeImmune's Dividend Payout Ratio or its related term are showing as below:

GBIM's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.435
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-05-21), the Dividend Yield % of GlobeImmune is 0.00%.

GlobeImmune's Dividends per Share for the months ended in Mar. 2016 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

GlobeImmune Dividend Payout Ratio Historical Data

The historical data trend for GlobeImmune's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeImmune Dividend Payout Ratio Chart

GlobeImmune Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dividend Payout Ratio

Get a 7-Day Free Trial

GlobeImmune Quarterly Data
	Dec10	Mar11	Jun11	Dec11	Mar12	Jun12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of GlobeImmune's Dividend Payout Ratio

For the Biotechnology subindustry, GlobeImmune's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

GlobeImmune's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GlobeImmune's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where GlobeImmune's Dividend Payout Ratio falls into.

GlobeImmune Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

GlobeImmune's Dividend Payout Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2015 )	/	EPS without NRI (A: Dec. 2015 )
	=	0	/	-0.48
	=	N/A

GlobeImmune's Dividend Payout Ratio for the quarter that ended in Mar. 2016 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Mar. 2016 )	/	EPS without NRI (Q: Mar. 2016 )
	=	0	/	-0.15
	=	N/A

GlobeImmune (OTCPK:GBIM) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

GlobeImmune Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of GlobeImmune's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

GlobeImmune (GlobeImmune) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeImmune Inc (OTCPK:GBIM) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

1450 Infinite Drive, Louisville, CO, USA, 80027

Website

http://www.globeimmune.com

GlobeImmune Inc is a US-based biopharmaceutical company which focuses on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen platform. It develops few Tarmogen product candidates for infectious disease and multiple cancer indications. The pipeline products of the company are GS-4774, GI-19000, GI-2010, GI-18000 which targets HBV and HIV antigens, TB antigens and Delta virus antigens and Oncology product candidates such as GI-6207, GI-6301, GI4000 which targets Carcinoembryonic antigen, Brachyury, and Mutated Ras.

Executives

Augustine Lawlor	director	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Daniel J Mitchell	director
S. Edward Torres	director	C/O LILLY VENTURES FUND I LLC, 115 W. WASHINGTON ST, STE 1680 SOUTH, INDIANAPOLIS IN 46204
Healthcare Ventures Vii Lp	other: Former 10% Owner	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
John W Littlechild	other: Former 10% Owner	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
James H Cavanaugh	other: Former 10% Owner	265 HOTHORPE LANE, VILLANOVA PA 19085
Harold R Werner	other: Former 10% Owner	C/O HEALTHCARE VENTURES LLC, 44 NASSAU STREET, PRINCETON NJ 08542
Christopher Mirabelli	other: Former 10% Owner	55 CAMBRIDGE PARKWAY, SUITE 301, CAMBRIDGE MA 02142
Healthcare Partners Vii, L.p.	other: Former 10% Owner	44 NASSAU STREET, PRINCETON NJ 08542
J William Freytag	director
Rodell Timothy C Jr	director, officer: CEO & Pres	201 MIDLAND AVE, ASPEN CO 81611
Celgene Corp /de/	10 percent owner	86 MORRIS AVENUE, SUMMIT NJ 07901
Morgenthaler Partners Vii Lp	10 percent owner	50 PUBLIC SQUARE, SUITE 2700, CLEVELAND OH 44113

GlobeImmune (GlobeImmune) Headlines

No Headlines